Menarini Group Presents Updated Results from Pivotal Phase 3 E...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FLORENCE, Italy, November, 30, 2022, /PRNewswire-AsiaNet/-- - Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors- Elacestrant side effects were manageable...
Authors: LATEST ASIANET NEWS RELEASES